Lidoderm Antitrust

A drug maker that dropped its patent suit against makers of the pain patch Lidoderm and agreed to delay its generic version could have won its lawsuit, an “alternate injury in a but-for world” that precludes resolving a sprawling antitrust class action in the drug makers’ favor, a federal judge has ruled.

SAN FRANCISCO – A drug maker that dropped its patent suit against makers of the pain patch Lidoderm and agreed to delay its generic version could have won its lawsuit, an “alternate injury in a but-for world” that precludes resolving a sprawling antitrust class action in the drug makers’ favor, a federal judge has ruled.

Categories / Business, Courts, Health

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Lidoderm Antitrust

Subscribe to Closing Arguments

Additional Reads